¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£ÇÐȸ (¿Â¶óÀÎ) The Liver Week 2021 Virtual Confernence Day 2 : 2021-05-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°£ÇÐȸ (¿Â¶óÀÎ) The Liver Week 2021 Virtual Confernence Day 2 : 2021-05-14
±³À°ÀÏÀÚ : 2021-05-14
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) The Liver Week 2021 Virtual Confernence Day 2      
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ Áغñ»ç¹«±¹
¿¬¶ôó : 02-373-1005  
À̸ÞÀÏ : kaslsecretariat@hbni.co.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 24 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 110,000¿ø      
ºñ°í Member-70,000/ Resident, Trainee, Fellow, Researcher, Army Doctor, Nurse, or Others-40,000 Non-Member, Healthcare Professional-110,000 International Delegate-USD 75 Foreign Investigator Award Winner-USD 40      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:20~08:40 Clinical Implication of Personalized Medicine in Hepatology  Yeul Hong Kim(Korea Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:40~09:00 Personalized Medicine in NAFLD: From Genetics and Systems Biology  Silvia Sookoian(Univ. of Buenos Aires Argentina) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:00~09:20 Personalized Medicine in Liver Disease via Modulating the Gut Microbiota  Ki Tae Suk(Hallym Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:20~09:40 Personalized Medicine in Autoimmune Hepatitis  Atsumasa Komori(National Hospital Organization Nagasaki Medical Center Japan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:10~11:35 To Be Confirmed  Jeong-Hoon Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:35~12:00 Optimizing the Secondary Prevention of HCC in Patients with Chronic Hepatitis B: A Lesson from Real-World Evidence  Jonggi Choi(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 12:00~12:30 To Be Confirmed  Ju Dong Yang(Cedars-Sinai Medical Center USA) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:30~13:50 Advancing Age and Comorbidity in Patients with Chronic Hepatitis B  Yun Bin Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:50~14:10 Hepatocellular Carcinoma Prediction Model for Antiviral-Treated Chronic Hepatitis B Patients  Hwi Young Kim(Ewha Womans Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:10~14:30 Clinical Implications of Novel Biomarkers of Hepatitis B Virus  Man-Fung Yuen(The Univ. of Hong Kong Hong Kong) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:30~14:50 HBV-Host Genome Integration: How Can We Detect It and What Is Its Impact?  Thomas Tu(The Univ. of Sydney Australia) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:00~15:40 Progress and Challenges in Achieving Hepatitis B Virus Elimination  Fabien Zoulim(National Institute for Health and Medical Research France) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:40~16:20 Acute-on-Chronic Liver Failure: Achievements and Future Perspectives  Shiv Kumar Sarin(Institute of Liver & Biliary Science India) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:30~16:50 Individualized Risk Stratification of Compensated Advanced Chronic Liver Disease (cACLD)  Annalisa Berzigotti(Univ. of Bern Switzerland) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:50~17:10 How to Prevent Decompensation in Compensated Cirrhosis  Moon Young Kim(Yonsei Univ. Wonju) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:10~17:30 Current and Novel Treatment Strategies of Hepatic Encephalopathy  Rajiv Jalan(Univ. College London UK) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:30~17:50 Understanding Coagulation and Hemostasis in Cirrhosis  Jung Il Lee(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:20~08:40 LI-RADS Classification and Its Impact on the Prognosis of Primary Liver Cancer  Sang Hyun Choi(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:40~09:00 Imaging Phenotype of Hepatocellular Carcinoma Subtypes  Jin-Young Choi(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:00~09:20 Different Hepatocellular Carcinoma Risk and Surveillance Strategies According to Situations: Young Age  Nae-Yun Heo(Inje Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:20~09:40 Different Hepatocellular Carcinoma Risk and Surveillance Strategies According to Situations: After Virologic Cure  Jung Hyun Kwon(The Catholic Univ. of Korea) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:10~11:30 Role of Systemic Therapy in Intermediate-Stage Hepatocellular Carcinoma  Masatoshi Kudo(Kindai Univ. Japan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:30~11:50 Role of Loco-Regional Treatment in Advanced-Stage Hepatocellular Carcinoma  Ju Hyun Shim(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:50~12:10 Optimizing Radiotherapy with Immune Checkpoint Blockade in Hepatocellular Carcinoma  Jeong Il Yu(Sungkyunkwan Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 12:10~12:30 Treatment of Advanced Hepatocellular Carcinoma with Child-Pugh B Cirrhosis  Chang Wook Kim(The Catholic Univ. of Korea) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:30~13:50 Selecting First-Line Therapy for Advanced Hepatocellular Carcinoma: TKI vs. ICI  Kyung-Hun Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:50~14:10 How to Optimize Sequencing of Systemic Treatment in Advanced Hepatocellular Carcinoma  Ann-Lii Cheng(National Taiwan Univ. Taiwan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:10~14:30 HCC Patients on Systemic Therapy: Prediction of Prognosis  Beom Kyung Kim(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:30~14:50 Assessment of Tumor Response in Patients Receiving Systemic Therapy: RECIST 1.1, Modified RECIST or Other Options  Min-Hee Ryu(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:00~15:20 Expanding Criteria for Liver Transplantation: Sero-Positive Donors  Hae Won Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:20~15:40 HCC Recurrence after Liver Transplantation: Risk Factors  Wonseok Kang(Sungkyunkwan Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:40~16:00 Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation: Surgery and Locoregional Therapy  Dong-Hwan Jung(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:00~16:20 Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation: Systemic Therapy  Bo Hyun Kim(National Cancer Center Korea) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:20~08:40 ABO-Incompatible Living Donor Liver Transplantation and Biliary Complications  Gi-Won Song(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:40~09:10 ABO-Incompatible Living Donor Liver Transplantation in High-Risk Patients: Hepatocellular Carcinoma and Infection  Dong-Jin Joo(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:10~09:30 Optimal Protocol to Overcome Weak Points of ABO-Incompatible Living Donor Liver Transplantation  Nam-Joon Yi(Seoul National Univ.) 
Åä·Ð 05-14 ¿Â¶óÀÎ °³ÃÖ 09:30~09:40 Discussion  () 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:10~11:40 Post-Transplant Lymphoproliferative Disorder after Liver Transplantation  Olivia Martinez(Stanford Univ. USA) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:40~11:50 Discussion  () 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:50~12:20 Outcome of Liver Retransplantation Using Living Donor Grafts  Kaori Kuramitsu(Kobe Univ. Japan) 
Åä·Ð 05-14 ¿Â¶óÀÎ °³ÃÖ 12:20~12:30 Discussion  () 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:30~13:50 Preoperative Assessment of Liver Function in Patients Requiring Hepatectomy)  Young Seok Han(Kyungpook National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:50~14:10 Prevention of Post Hepatectomy Liver Failure (PHLF): Where Are We? (PVE, ALPPS, HVE, Ischemic Preconditioning)  Albert Chan(The Univ. of Hong Kong Hong Kong) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:10~14:30 Early Detection of PHLF and Non-Surgical Management of PHLF  Dong-Sik Kim(Korea Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:30~14:50 Timing and Results of Liver Transplantation for PHLF  Pål-Dag Line(Univ. of Oslo Norway) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:20~08:40 Targeting cccDNA for Cure of Hepatitis B Virus Infection  Kyun-Hwan Kim(Sungkyunkwan Univ) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 08:40~09:00 Unresolved Issues of Immune Tolerance in Chronic Hepatitis B: Earlier Treatment the Better?  Hye Won Lee(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:00~09:20 Prognostic Impact of Concurrent Hepatic Steatosis in Chronic Hepatitis B: Can Lifestyle Modification Reduce HCC Risk?  Yun Bin Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 09:20~09:40 Chemopreventive Strategies of HBV-related HCC: The Emerging Role of Non-viral Risk Factors  Jonggi Choi(Univ. of Ulsan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:10~11:30 Introduction of the Useful Big Database for Researchers in NAFLD  Donghee Kim(Stanford Univ. USA) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:30~11:50 MAFLD and Cardiovascular Disease  Jian-Gao Fan(Shanghai Jiao Tong Univ. China) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 11:50~12:10 From NASH to Diabetes vs. from Diabetes to NASH: Different or Similar in Treatment?  Yongho Lee(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 12:10~12:30 How NAFLD Patients Die: Heart, Liver, or Other Cancers?  Jeong-Ju Yoo(Soonchunhyang Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:30~13:50 Update on Histopathology in Autoimmune Hepatitis  Haeryoung Kim(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 13:50~14:10 Interpretation of Autoantibody Tests for Autoimmune Liver Diseases  Yun-Jong Lee(Seoul National Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:10~14:30 Management of Difficult Cases of Autoimmune Hepatitis and New Therapeutics  Atsumasa Komori(National Hospital Organization Nagasaki Medical Center Japan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 14:30~14:50 Update on Management of Primary Biliary Cholangitis  Kyung-Ah Kim(Inje Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:00~15:20 Measurement of Hepatic Venous Pressure Gradient (HVPG) and Its Clinical Significance during TIPS or PARTO: Tips and Pitfalls  Hitoshi Maruyama(Juntendo Univ. Japan) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:20~15:40 Application of HVPG for Predicting Prognosis in Liver Cirrhosis  Young Chang(Soonchunhyang Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 15:40~16:00 Tailored Treatment of Cirrhotic Complications According to HVPG  Jung Gil Park(Yeungnam Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:00~16:20 Non-Invasive Estimation of HVPG: Could It Be an Alternative?  Young Seo Cho(Hanyang Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:30~16:50 Microbiome as a Potential Diagnostic Biomarker in Severe Alcoholic Hepatitis  Soon Sun Kim(Ajou Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:50~17:10 Prognosis and Outcome of Patients with Alcohol-Associated Acute-On-Chronic Liver Failure  Eileen L. Yoon(Hanyang Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:10~17:30 Clinical, Histological and Molecular Profiling of Different Stages of Alcohol-Related Steatohepatitis  Ramon Bataller(Univ. of Pittsburgh USA) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:30~17:50 Non-Invasive Diagnostic Biomarkers in Alcohol-Related Liver Disease  Young Kul Jung(Korea Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 16:30~17:05 Latest Treatment Drugs Hepatitis B, C and Treatment of Hepatitis D, E  Wonseok Kang(Sungkyunkwan Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:05~17:40 Liver Transplantation with Renal Failure  Man Ki Ju(Yonsei Univ.) 
±³À°½Ã°£ 05-14 ¿Â¶óÀÎ °³ÃÖ 17:40~18:00 Latest Issues in the Liver Transplant Site  Hyung Sook Kim(Seoul ST. Mary¡¯s Hospital) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£ÇÐȸ (¿Â¶óÀÎ) The Liver Week 2021 Virtual Confernence Day 2 : 2021-05-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021 Ãæ³²´ëÇб³º´¿ø ºñ´¢ÀÇÇаú ÇÕµ¿ ½ÉÆ÷Áö¿ò : 2021-05-14
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) 1Çбâ À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ(COVID-19 Ä¡·á º´¿ø¿¡¼­ ¾òÀº °æÇè) : 2021-05-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 23 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 23 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 30 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 27 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 25 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 15 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 7 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 6 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 13 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 11 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 5 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 17 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 9 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 15 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 12 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷